



Media Releases » **Torrent Pharma announces Q2 FY 2016-17 Results.**
October 26th, 2016

Financial Highlights	Q2 FY 15-16	Q2 FY 14-15	Growth	HS 15-17	HS 14-16	Growth
Revenue	1,429	1,093	+49%	2,580	2,542	+1%
EBITDA	372	307	+21%	554	1,172	-53%
%Revenue	26%	45%		20%	49%	
PBT (after Optional Items)	233	181	+29%	509	1,558	-67%
%Revenue	16%	40%		20%	42%	
PAT (after Optional Items)	207	168	+23%	488	1,168	-58%
%Revenue	14%	35%		17%	32%	
EPS	12.2	20.0	-39%	26.5	68.4	-61%

Amounts in \$ mil except per share data

Ahmedabad based Pharmaceuticals major, Torrent Pharmaceuticals Limited, today released its financial results for the Quarter ended 30th Sept 2016. **Quarterly Financials** • For Q2 FY 2016-17 revenues were at Rs. 1,429 crores as against Rs. 1,693 crores during the same period last year.

- EBIDTA for Q2 FY 2016-17 was at Rs. 372 crores as against Rs. 787 crores during the same period last year.
- PAT for Q2 2016-17 was at Rs. 207 crores as against Rs.509 crores during the same period last year.

- Previous period include exceptional revenues and profits which was primarily on account of the launch of a new product in US market, which had limited competition.
 - Research and development spend during the quarter was up by Rs 54 Crores, from Rs. 57 Crores in the same period previous year to Rs. 111 Crores.
- The Company acquired API manufacturing unit of Glochem Industries in Vizag on a going concern slump sales basis on 03rd Sept 2016.

Q2 PERFORMANCE HIGHLIGHTS

India Business

- Domestic formulation business recorded revenues of Rs. 496 crores for Q2 FY 2016-17 v/s Rs. 442 crores for the same period last year, showing 12% growth.

Discontinuance of certain promotional schemes and hygiene initiatives has impacted the business in short term however it will have positive impact in long term.

Brazil Business

- Brazilian business recorded revenues of Rs. 157 crores for Q2 FY 2016-17 v/s Rs. 131 crores for the same period last year, showing 20% growth.

USA

- US business recorded revenues of Rs. 322 crores for Q2 FY 2016-17 v/s Rs. 712 crores for the same period last year.
- Previous period include exceptional revenues, primarily on account of the launch of a new product which had limited competition.

Germany • German business recorded revenues of Rs. 186 crores for Q2 FY 2016-17 v/s Rs. 163 crores for the same period last year, showing 14% growth.

H1 PERFORMANCE HIGHLIGHTS

India Business

- Domestic formulation business recorded revenues of Rs. 1,006 crores for H1 FY 2016-17 v/s Rs. 934 crores for the same period last year, showing 8% growth. Discontinuance of certain promotional schemes and hygiene initiatives has impacted the business in short term however it will have positive impact in long term.

Brazil Business

- Brazilian business recorded revenues of Rs. 325 crores for H1 FY 2016-17 v/s Rs. 269 crores for the same period last year, showing 21% growth.

USA

- US business recorded revenues of Rs. 755 crores for H1 FY 2016-17 v/s Rs. 1600 crores for the same period last year.
- Previous period include exceptional revenues, primarily on account of the launch of a new product which had limited competition.

Germany

- German business recorded revenues of Rs. 373 crores for H1 FY 2016-17 v/s Rs. 321 crores for the same period last year, showing 16% growth.

About Torrent Pharma

Torrent Pharma, with annual revenues of more than Rs. 6600 crores is the flagship Company of the Rs. 18,300 crore Torrent Group.

Torrent Pharma continues to be at the forefront of the Indian pharmaceutical industry with many of its products ranking among the top 500 brands (AIOCD Dataset) in India. Its widespread international presence also includes several markets where Torrent is amongst the leading pharmaceutical companies in the respective countries.

Torrent has a fully equipped Research Center, employing almost 900 scientists, to support the Company's operations and product pipeline for both Domestic and Overseas markets. The Company's manufacturing plants located at Indrad, Baddi, Sikkim, Dahej, Pithampur and Vizag have facilities to produce Formulations and Bulk drugs. The plants are approved by authorities from various regulated and semi regulated markets like US, UK, Brazil, Germany, Australia and South Africa.